Clarithromycin hameln

GIF decision: Withdrawal from market, Marketing prohibition

What does this decision mean?

  • Wycofanie z obrotu — Some of the products covered by the decision were withdrawn from the market — please return them to the pharmacy/distributor.
  • Zakaz wprowadzania — Selected batches are subject to a marketing prohibition — the product cannot be distributed to pharmacies.

Lack of confirmed quality of the active substance used for batch 25D052 and non-compliance with GMP requirements in the supply chain. The product is a solution for infusion, so potential quality deviations carry an increased risk to patients' health and life. Potential effects: poisoning, lack of efficacy, complications during intravenous therapy.

Download the app and stay informed

Get instant notifications about recalled products and protect your family.

Clarithromycin hameln
Risk Level
Critical
Manufacturer
hameln Pharma GmbH z siedzibą w Hameln, Niemcy
Batch Number
25D052
Notice Date
18.12.2025
View official statement

Related

Other Notices